logo
Plus   Neg
Share
Email

Lilly Reports Positive Results From Taltz 5-yr Study - Quick Facts

Eli Lilly and Company (LLY) said the results from a five-year Phase 3 study for Taltz (ixekizumab) demonstrated that patients with moderate- to severe plaque psoriasis taking Taltz can achieve sustained skin clearance over the five-year treatment period. No unexpected safety outcomes were reported, the company said.

Later in the year, Eli Lilly plans to announce the results from IXORA-R, a clinical trial designed to evaluate superiority between Taltz and Tremfya (guselkumab) in adult patients with moderate- to severe plaque psoriasis.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Boeing said Sunday that it had informed the Federal Aviation Administration and international regulators on multiple occasions about the expanded role of the flight-control software in 737 MAX, which was linked to two fatal crashes that killed 346 people. The U.S. Department of Justice has reached a settlement agreement with a Texas-based Taco Bell franchise owner for immigration-related discrimination against certain employees. The settlement resolves the DOJ's investigation into whether MUY Brands LLC, and a related management company, MUY Consulting Inc., violated the Immigration and Nationality Act. Starbucks is gearing up for the upcoming holiday season by introducing its 2019 holiday flavors in U.S. grocery stores. The launch of the coffee giant's holiday line-up this year includes returning holiday favorites as well as a new item. Customers can now take home products that are making a comeback such as Starbucks Holiday Blend K-Cup and Ground Coffee, Peppermint Mocha Flavored Ground Coffee,
Follow RTT
>